PD-1 Silent PSMA/PSCA Targeted CAR-T for the Treatment of Prostate Cancer
Status:
Recruiting
Trial end date:
2024-08-30
Target enrollment:
Participant gender:
Summary
This is a phase I study which will test the safety of different doses of the patients own
immune cells which have been changed to help recognize and destroy the cancer cells. The
investigators want to find out what effects, good and/or bad, it has on the body and on the
prostate cancer. The immune cells (T cells) used in this study will be the patients own
immune cells. They will be removed from the patients blood, changed in the laboratory, and
then put back into their body. T cells help the body fight infections. These cells may also
kill cancer cells in some cases. Right now the patients T cells are unable to kill the cancer
cells. For this reason, the physician will change the T cells by putting in a gene so that
they may be able to better recognize and kill the prostate cancer cells. A gene is a portion
of information which comes from the DNA and tells the cell what to do. This gene will be put
into the patients T cells by a weakened virus. It is hoped that this approach will help the T
cells recognize the prostate cancer tumor cells and possibly kill them. This is an entirely
new treatment for prostate cancer and it is not known if it will have any beneficial or
unexpected harmful effects.